ABL Bio Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Seongnam Korea, Republic of (2016)

Organization Overview

First Clinical Trial
2017
NCT03292783
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

ABL Bio Inc. | ABL Bio, Inc.

Active Ingredients

Drugs in Phase 2 Trials (3)

asciminib (Scemblix) (1 trial)

irinotecan (Camptosar) (1 trial)

paclitaxel (taxol) (1 trial)

Drugs in Phase 1 Trials (5)

abl103 (1 trial)

abl301 (1 trial)

abl501 (1 trial)

abl503 (1 trial)

nov1501 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 8